Related Experiment Video
Updated: Aug 7, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Chronic hepatitis C therapy: changing the rules of duration
1Center for Hepatitis C, Atlanta Medical Center, 30312, USA. brianpearlman@hotmail.com
Summary
Shortening hepatitis C therapy may save costs and reduce side effects. Tailoring treatment duration based on viral response and genotype can maintain effectiveness for many patients.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C treatment durations are traditionally fixed.
- Modifying therapy length may offer benefits like cost savings and reduced side effects.
- Individualized treatment may improve sustained virologic response rates.
Purpose of the Study:
- To review evidence for individualizing hepatitis C treatment durations.
- To discuss potential modifications to treatment algorithms based on patient factors.
Main Methods:
- Review of clinical and viral kinetic studies.
- Analysis of treatment outcomes based on hepatitis C genotype, viral load, and response kinetics.
- Discussion of treatment individualization strategies.
Main Results:
- Shortened durations (12-16 weeks) may be effective for genotype 2 and 3 patients with undetectable viremia at 4 weeks.
- Abbreviated courses may be unsuitable for advanced fibrosis or high viral load genotype 3 infections.
- 24-week regimens may be feasible for genotype 1 patients with rapid virologic response and low viral load.
- Extended therapy might benefit slow virologic responders with genotype 1 and high viral loads, requiring prospective validation.
Conclusions:
- Treatment individualization for chronic hepatitis C is supported by current evidence.
- Tailoring therapy duration based on genotype, viral load, and response can optimize outcomes.
- Further prospective studies are needed to validate extended therapy for specific patient groups.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...